Hyaluronic acid-coated and Olaparib-loaded PEI - PLGA nanoparticles for the targeted therapy of triple negative breast cancer
AIM: To prepare the hyaluronic acid-coated Olaparib-loaded PEI - PLGA nanoparticles (HA-Ola-PPNPs) and investigate their tumour-targeted anticancer effect.
METHODS: The synthesis of HA-Ola-PPNPs was verified by DLS, TEM and SEM, followed was measured its cytotoxicity using CCK-8 assay. Confocal microscopy was used to observe the cellular uptake. Cell apoptosis was analysed by flow cytometry, biological SEM, and TEM. The expression of related proteins within the tumour site was investigated by immunostaining.
RESULTS: The prepared HA-Ola-PPNPs showed a diameter of ∼160 nm with a negatively charged surface (-16.9 ± 2.7 mV) and sustained drug release behaviour. And the encapsulation efficiency of HA-Ola-PPNPs was 78.63 ± 5.29%. HA-Ola-PPNPs exhibited efficient in vitro and in vivo antitumor activities. HA-Ola-PPNPs induced cell apoptosis by upregulating Bax, Cytochrome C, and Caspase 3, downregulating Bcl-2 in breast cancer-bearing mice.
CONCLUSIONS: According to the results, the Ola-loaded and HA-coated PEI - PLGA nanoparticles could be considered as a powerful tumour-targeted drug delivery system for TNBC treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 39(2022), 1 vom: 03. Jan., Seite 25-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Huiping [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9004-61-9 |
|---|
| Anmerkungen: |
Date Completed 15.02.2022 Date Revised 01.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2021.2014586 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33396540X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33396540X | ||
| 003 | DE-627 | ||
| 005 | 20231225222730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2021.2014586 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM33396540X | ||
| 035 | |a (NLM)34859741 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Huiping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyaluronic acid-coated and Olaparib-loaded PEI - PLGA nanoparticles for the targeted therapy of triple negative breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2022 | ||
| 500 | |a Date Revised 01.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To prepare the hyaluronic acid-coated Olaparib-loaded PEI - PLGA nanoparticles (HA-Ola-PPNPs) and investigate their tumour-targeted anticancer effect | ||
| 520 | |a METHODS: The synthesis of HA-Ola-PPNPs was verified by DLS, TEM and SEM, followed was measured its cytotoxicity using CCK-8 assay. Confocal microscopy was used to observe the cellular uptake. Cell apoptosis was analysed by flow cytometry, biological SEM, and TEM. The expression of related proteins within the tumour site was investigated by immunostaining | ||
| 520 | |a RESULTS: The prepared HA-Ola-PPNPs showed a diameter of ∼160 nm with a negatively charged surface (-16.9 ± 2.7 mV) and sustained drug release behaviour. And the encapsulation efficiency of HA-Ola-PPNPs was 78.63 ± 5.29%. HA-Ola-PPNPs exhibited efficient in vitro and in vivo antitumor activities. HA-Ola-PPNPs induced cell apoptosis by upregulating Bax, Cytochrome C, and Caspase 3, downregulating Bcl-2 in breast cancer-bearing mice | ||
| 520 | |a CONCLUSIONS: According to the results, the Ola-loaded and HA-coated PEI - PLGA nanoparticles could be considered as a powerful tumour-targeted drug delivery system for TNBC treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Olaparib | |
| 650 | 4 | |a PEI-PLGA nanoparticles | |
| 650 | 4 | |a TNBC | |
| 650 | 4 | |a Targeted delivery system | |
| 650 | 4 | |a hyaluronic acid | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Phthalazines |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 650 | 7 | |a olaparib |2 NLM | |
| 650 | 7 | |a WOH1JD9AR8 |2 NLM | |
| 700 | 1 | |a Zhang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Wenting |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a He, Zihao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kaiping |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Chen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 39(2022), 1 vom: 03. Jan., Seite 25-36 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:1 |g day:03 |g month:01 |g pages:25-36 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2021.2014586 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 1 |b 03 |c 01 |h 25-36 | ||